DRD5

dopamine receptor D5

Explore in graph →CI-GENE-00043875HGNC:3026 ENSG00000169676 NCBI 1816 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DRD5 low expression1
Dordaviprone	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7600 In the phase 2 trial, patients with recurrent glioblastoma were treated with dopamine receptor D2 (DRD2) antagonist ONC201. DRD5 is a dopamine receptor family member that opposes DRD2 signaling. All t… (full text at CIViC) PMID 30559168 · Prabhu et al., 2019 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (9)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved9 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Metaplastic Breast Cancer (MSK,NPJ Breast Cancer 2021) mbc_msk_2021	Breast Metaplastic Carcinoma	Ssm	1

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.